ARCHIVES

Phase II Elotuzumab Study Demonstrates 33 Months PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

NCI Tells CCOPs To Slow Patient Accrual To Clinical Trials, Prepare For Budget Cuts.

May 12, 2006

Benefit Of Chemotherapy Depends ER Status

April 28, 2006

ASCO, AACR Honor Scientists, Journalists At Annual Meetings

May 29, 1992

NIH Considering Intramural NRSA, NCI Advisors Not Enthusiastic

February 17, 1984

Funding Opportunities. (8-page issue).

May 2, 2003

Study Finds Long-Term Remission In NHL With Tositumomab, Iodine I 131 With CHOP

December 30, 2005